TAVR, or transcatheter aortic valve replacement, is a minimally invasive heart procedure that replaces a diseased aortic valve without open-heart surgery. Instead of opening the chest, a doctor threads a compressed replacement valve through a blood vessel, guides it to the heart, and expands it inside the old valve. Most patients go home the same day or the next and return to normal activity within about a week.
How TAVR Works
Your aortic valve sits between the heart’s main pumping chamber and the aorta, the large artery that carries blood to the rest of your body. When this valve becomes stiff and narrowed (a condition called aortic stenosis), the heart has to work much harder to push blood through. Over time, that extra strain causes fatigue, chest pain, shortness of breath, and fainting.
In TAVR, a new valve made of animal tissue is crimped down and loaded onto a thin, flexible tube called a catheter. The catheter is inserted into a blood vessel, most often in the groin, and advanced to the heart under real-time X-ray imaging. Once the new valve reaches the right position inside the old one, it’s expanded. Some valves expand using a small balloon inflated by the doctor, while others are made from a nickel-titanium alloy that springs open on its own once released. The calcium deposits that stiffened the old valve actually help hold the new one in place, pressing against the frame like a friction fit. The old valve stays where it is; it’s simply pushed aside as the new valve takes over.
Who Is a Candidate
TAVR was originally reserved for patients too sick or too old for open-heart surgery. That has changed significantly. Clinical trials like PARTNER III showed that in low-risk patients, TAVR matched surgical valve replacement in outcomes including mortality, stroke, and rehospitalization at one year. Current guidelines from both American and European cardiology societies now endorse TAVR across a range of risk levels, though they differ on specifics like age cutoffs and when to intervene in patients who haven’t developed symptoms yet.
The decision between TAVR and traditional surgery typically involves a heart team weighing your anatomy, age, other health conditions, and personal preferences. One factor that matters a great deal is whether the catheter can safely travel through your blood vessels to reach the heart.
How Doctors Prepare for the Procedure
Before TAVR, you’ll undergo a CT scan that has become central to planning the procedure. The scan measures the exact size and shape of your aortic valve opening so the team can choose the right replacement valve. It also maps the blood vessels the catheter will travel through, flagging potential problems like significant twisting, calcium buildup, or aneurysms that could make the standard groin approach risky. If the femoral artery in the groin isn’t suitable (roughly 10 to 15 percent of cases), the team may route the catheter through an artery near the collarbone or, less commonly, through other access points.
What Recovery Looks Like
For the majority of patients who have TAVR through the groin, the hospital stay is remarkably short: same day or one night. If the procedure requires a small chest incision instead, the stay extends to several days. In the first week at home, you’ll need to avoid lifting anything over 10 pounds and skip strenuous activities like jogging, golf, or tennis for about five days. Stairs are fine, just take them slowly. You shouldn’t drive until your doctor clears you, and bathing or swimming needs to wait until the catheter insertion site has fully healed.
Most people notice a meaningful improvement in how they feel by their 30-day follow-up visit, with further gains by six months. Studies consistently show that patients improve by at least one full functional class after TAVR, meaning activities that previously left them breathless or exhausted become manageable again. That improvement holds for at least three years in the majority of patients.
Blood Thinners After TAVR
After the procedure, most patients without a separate reason to take blood thinners are placed on low-dose aspirin, often for life. Guidelines had previously recommended adding a second anti-clotting medication for the first three to six months, but a randomized trial published in the New England Journal of Medicine found that aspirin alone actually resulted in fewer bleeding events and fewer combined bleeding or clot-related complications at one year compared to the two-drug combination. Your care team will tailor the plan based on your individual risk factors.
Risks and Complications
TAVR is not risk-free, and the most important complications fall into a few categories.
- Paravalvular leak. Because the new valve sits inside the old one rather than being sewn in, small gaps can allow blood to seep backward around the frame. Some degree of leakage shows up on imaging in 50 to 85 percent of patients, but most of it is trivial or mild. Moderate to severe leakage, the kind that can affect heart function, occurs in roughly 3 to 10 percent of cases depending on the valve type and how well it’s sized.
- Need for a pacemaker. The new valve sits close to the heart’s electrical wiring. Expanding it can disrupt the signals that keep the heart beating in rhythm. In registry data, about 10 to 18 percent of patients need a permanent pacemaker afterward, with higher rates seen in self-expanding valve designs compared to balloon-expandable ones.
- Stroke. Dislodging bits of calcium or tissue during the procedure can block blood flow to the brain. Disabling stroke rates in large registries range from under 1 percent to about 2.3 percent, again varying by valve type.
How Long the New Valve Lasts
One of the biggest questions about TAVR has been durability, since the procedure is now offered to younger, lower-risk patients who need their valve to last decades. The longest follow-up data comes from the NOTION trial, which tracked patients for 10 years. At that point, severe structural valve deterioration (where the valve leaflets stiffen or tear enough to significantly impair function) had occurred in just 1.5 percent of TAVR patients, compared to 10 percent of those who had traditional surgical replacement. When moderate deterioration was included, the rates were closer together: 15.4 percent for TAVR and 20.8 percent for surgery, a difference that wasn’t statistically significant.
These 10-year numbers are encouraging, but they represent the earliest generation of transcatheter valves. Whether current designs will hold up over 15 or 20 years is still an open question, and it’s one of the main reasons the choice between TAVR and surgery in younger patients remains a careful, individualized discussion.